Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27506411 | 0.90 | TAAR1 (0.44) | TAAR1DRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL470870 | 0.87 | P2RX7 (0.43) | TAAR1SLC6A2SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL410563 | 0.87 | P2RX7 (0.43) | TAAR1SLC6A2SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL4977025 | 0.84 | SLC18A3 (0.44) | TAAR1SLC6A2SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL10409483 | 0.84 | SLC6A2 (0.40) | TAAR1SLC6A2SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL11706707 | 0.84 | TSHR (0.38) | TAAR1SLC6A2SLC6A4SLC6A3CHRNB2 | |
| Acetic Acid SCHEMBL27463978 | 0.84 | KCNH2 (0.43) | TAAR1DRD3 | |
| SCHEMBL470840 | 0.84 | CHRNB2 (0.41) | TAAR1SLC6A2SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL10409487 | 0.82 | SIGMAR1 (0.39) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL10958845 | 0.82 | SLC18A3 (0.39) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104529942-B | A kind of synthetic method of Vanoxerine | 天津孚音生物科技发展有限公司 | 2018-05-15 | — | — | CN | claimed |
| CN-104529942-A | Synthetic method for vanoxerine | TIANJIN FUYIN PHARMACEUTICAL INNOVATION CO LTD | 2015-04-22 | — | — | CN | claimed |
| US-20240082176-A1 | DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP AND TABLETS | PRODUCTOS FARMACEUTICOS, S.A. DE C.V. (MX) | 2024-03-14 | — | — | US | disclosed |
| US-20210128496-A1 | DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP OR TABLETS | Productos Farmaceuticos, S.A. DE C.V.s (MX) | 2021-05-06 | — | — | US | disclosed |
| CN-104529942-B | A kind of synthetic method of Vanoxerine | 天津孚音生物科技发展有限公司 | 2018-05-15 | — | — | CN | disclosed |
| EP-1773779-B1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIV LAVAL (CA) | 2013-12-04 | — | — | EP | disclosed |
| US-8557804-B2 | Nicotinic receptor agonists for the treatment of inflammatory diseases | UNIVERSITE LAVAL (CA) | 2013-10-15 | — | — | US | disclosed |
| US-8551983-B2 | Nicotinic receptor agonists for the treatment of inflammatory diseases | UNIVERSITE LAVAL (CA) | 2013-10-08 | — | — | US | disclosed |
| US-20120022049-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITE LAVAL (CA) | 2012-01-26 | — | — | US | disclosed |
| US-8039459-B2 | especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids | UNIVERSITE LAVAL (CA) | 2011-10-18 | — | — | US | disclosed |
| US-20080221085-A1 | Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases | UNIVERSITE LAVAL (CA) | 2008-09-11 | — | — | US | disclosed |
| EP-1773779-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITE LAVAL (CA) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006005195-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITé LAVAL (CA) | 2006-01-19 | — | — | WO | disclosed |
| US-4619929-A | SEDATIVES, HYPOTENSIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1986-10-28 | — | — | US | disclosed |
| US-4619929-A | SEDATIVES, HYPOTENSIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1986-10-28 | — | — | US | disclosed |
| EP-0056866-B1 | PHENYLPIPERAZINE DERIVATIVES OF HETERYLPHENOLS AND HETARYLANILINES, THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | BASF Aktiengesellschaft (DE) | 1985-06-19 | — | — | EP | disclosed |
| EP-0056866-A2 | Phenylpiperazine derivatives of heterylphenols and hetarylanilines, their preparation and their pharmaceutical compositions | BASF Aktiengesellschaft (DE) | 1982-08-04 | — | — | EP | disclosed |
| EP-0056866-A2 | Phenylpiperazine derivatives of heterylphenols and hetarylanilines, their preparation and their pharmaceutical compositions | BASF Aktiengesellschaft (DE) | 1982-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128496-A1 | DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP OR TABLETS | QDPR, IL5, CYP3A5 | TAAR1 2140/4885DRD2 56/4885DRD1 138/4885 |
| US-20080221085-A1 | Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases | CHRNA1, CHRNG, CHRM1 | TAAR1 30/4885DRD2 1400/4885DRD1 1947/4885 |
| US-20120022049-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CHRNA1, CHRNG, CHRM1 | TAAR1 30/4885DRD2 1400/4885DRD1 1947/4885 |
| US-20240082176-A1 | DROPROPIZINE IN COMBINATION WITH AMBROXOL IN THE DOSAGE FORM OF SYRUP AND TABLETS | QDPR, IL5, CYP3A5 | TAAR1 2071/4885DRD2 58/4885DRD1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.